Prince Pharmaceutical Co., Ltd. (6935.TWO)
TWD 21.7
(2.36%)
TWD 21.7
(2.36%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | 62.5 Million | 91.65 Million | 42.35 Million | -212 Thousand | 8.05 Million |
| Net Income | 19.16 Million | 64.2 Million | -10.3 Million | -41.44 Million | 9000.00 |
| Depreciation & Amortization | 58.55 Million | 52.35 Million | 46.22 Million | 28.37 Million | 13.1 Million |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | 6.27 Million | 2.92 Million | - | 2.02 Million | - |
| Change in working capital | -21.22 Million | -27.85 Million | 4.54 Million | 9.03 Million | -27.2 Million |
| Other non-cash items | 9.3 Million | 8.71 Million | 7.52 Million | 5.14 Million | 22.14 Million |
| Investing Cash Flow | -68 Million | -40.02 Million | -38.79 Million | -186.89 Million | -151.65 Million |
| Investments in PPE | -62.24 Million | -19.8 Million | -41.27 Million | -186.77 Million | -182.67 Million |
| Acquisitions | - | - | - | - | - |
| Investment purchases | - | - | - | - | -206 Thousand |
| Sales/Maturities of investments | 1.16 Million | 980 Thousand | 2.36 Million | - | - |
| Other Investing Activities | -6.98 Million | -21.25 Million | 1.34 Million | -191 Thousand | 31.02 Million |
| Financing Cash Flow | 56.11 Million | -52.17 Million | 11.86 Million | 69.13 Million | 172.67 Million |
| Debt repayment | -31.1 Million | -46.61 Million | -17.2 Million | -51.36 Million | -97.67 Million |
| Dividends payments | -5.42 Million | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | 100.23 Million | - | - | 22.7 Million | - |
| Other Financing Activities | 100.23 Million | -30 Million | -45 Million | -235.84 Million | 75 Million |
| Accounts receivables | -32.4 Million | -3.72 Million | -14.85 Million | 691 Thousand | -8.52 Million |
| Accounts payables | - | - | - | - | - |
| Inventory | 7.74 Million | -24.42 Million | -32.09 Million | -14.3 Million | -15.2 Million |
| Other working capital | -13.86 Million | 9.51 Million | 22.49 Million | 16.54 Million | -3.48 Million |
| Cash at beginning of period | 71.95 Million | 72.49 Million | 57.07 Million | 175.05 Million | 145.98 Million |
| Cash at end of period | 122.56 Million | 71.95 Million | 72.49 Million | 57.07 Million | 175.05 Million |
| Capital Expenditure | -62.24 Million | -19.8 Million | -41.27 Million | -186.77 Million | -182.67 Million |
| Effect of forex changes on cash | - | - | - | - | - |
| Net cash flow / Change in cash | 50.6 Million | -540 Thousand | 15.42 Million | -117.97 Million | 29.07 Million |
| Free Cash Flow | 256 Thousand | 71.84 Million | 1.08 Million | -186.98 Million | -174.62 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -12.41 Million | -12.41 Million | 4.79 Million | 19.16 Million | 4.79 Million | 2.85 Million |
| Depreciation & Amortization | 15.43 Million | 15.43 Million | 15.08 Million | 58.55 Million | 15.08 Million | 14.19 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 1.42 Million | - | 1.55 Million | 6.27 Million | 1.55 Million | 1.58 Million |
| Change in working capital | 563.5 Thousand | 563.5 Thousand | -3.56 Million | -21.22 Million | -3.56 Million | -15.69 Million |
| Other non-cash items | -2.53 Million | -1.11 Million | 12.22 Million | 9.3 Million | 12.22 Million | -1.78 Million |
| Investing Cash Flow | -5.08 Million | -5.08 Million | -12.77 Million | -68 Million | -12.77 Million | -21.23 Million |
| Investments in PPE | -5.25 Million | -5.25 Million | -19.43 Million | -62.24 Million | -19.43 Million | -11.58 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | 1.16 Million | - | - |
| Other Investing Activities | 171.5 Thousand | 171.5 Thousand | 6.66 Million | -6.98 Million | 6.66 Million | -9.64 Million |
| Financing Cash Flow | -8.51 Million | -8.51 Million | -7.32 Million | 56.11 Million | -7.32 Million | 35.38 Million |
| Debt repayment | - | - | - | -31.1 Million | - | - |
| Dividends payments | - | - | -2.71 Million | -5.42 Million | -2.71 Million | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | 100.23 Million | - | - |
| Other Financing Activities | -8.51 Million | -8.51 Million | -4.61 Million | 100.23 Million | -4.61 Million | 35.38 Million |
| Accounts receivables | -4.06 Million | -4.06 Million | 4.15 Million | -32.4 Million | 4.15 Million | -20.35 Million |
| Accounts payables | - | - | - | - | - | - |
| Inventory | 2.39 Million | 2.39 Million | -4.91 Million | 7.74 Million | -4.91 Million | 8.78 Million |
| Other working capital | 2.23 Million | 2.23 Million | -2.8 Million | -13.86 Million | -2.8 Million | -4.12 Million |
| Cash at beginning of period | - | - | - | 71.95 Million | - | - |
| Cash at end of period | -11.14 Million | -11.14 Million | 9.99 Million | 122.56 Million | 9.99 Million | 15.3 Million |
| Capital Expenditure | -5.25 Million | -5.25 Million | -19.43 Million | -62.24 Million | -19.43 Million | -11.58 Million |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -11.14 Million | -11.14 Million | 9.99 Million | 50.6 Million | 9.99 Million | 15.3 Million |
| Free Cash Flow | -2.79 Million | -2.79 Million | 10.66 Million | 256 Thousand | 10.66 Million | -10.43 Million |
CAA
ALUP11
3787
TAVERNIER
0HST
SAPMF